trial

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

NCTId NCT01626456
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 478 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2015-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
478 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Quadruple
Start
2012-06
Primary completion
2015-04
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
ALKS 9072, LowALKS 9072, High

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Alkermes Medical Director, MDStudy Director

Sites

82 total
Little Rock, United StatesLittle Rock, United StatesSpringdale, United StatesGarden Grove, United StatesLa Habra, United StatesOakland, United StatesOceanside, United StatesSan Diego, United StatesWashington D.C., United StatesFort Lauderdale, United StatesLeesburg, United StatesAtlanta, United States

Linked catalysts

1
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) — primary completion2015-04

Facts & assertions

4 sourced
Enrollment
478
Phase
PHASE3
Primary Completion Date
2015-04
Status
COMPLETED
relationships
The graph out of here
drug
ALKS 9072, Low
drug
ALKS 9072, High
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Alkermes Medical Director, MD
person